Interventions for managing medication-related osteonecrosis of the jaw

Interventions for managing medication-related osteonecrosis of the jaw

Cochrane Review 11 SoF Entries

Summary of Findings

Key results and quality assessments using GRADE methodology

Outcome Effect Participants Studies Certainty
Oral mucositis (moderate + severe) (BMT/SCT after conditioning for haematological cancers)
Placebo
0.89 - - Not assessed
Oral mucositis (moderate + severe) (RT to head and neck with cisplatin/5FU)
Placebo
0.91 - - Not assessed
Oral mucositis (moderate + severe) (CT alone for mixed cancers)
Placebo
0.56 - - Not assessed
Oral mucositis (severe) (BMT/SCT after conditioning for haematological cancers)
Placebo
0.85 - - Not assessed
Oral mucositis (severe) (RT to head and neck with cisplatin/5FU)
Placebo
0.79 - - Not assessed
Oral mucositis (severe) (CT alone for mixed cancers)
Placebo
0.3 - - Not assessed
Adverse events
Placebo
nan - - Not assessed
Oral mucositis (moderate + severe) (RT to head and neck)
Placebo/no treatment
0.72 - - Not assessed
Oral mucositis (severe) (BMT/SCT after conditioning for mixed cancers)
Placebo/no treatment
0.74 - - Not assessed
Oral mucositis (severe) (RT to head and neck)
Placebo/no treatment
0.31 - - Not assessed
Oral mucositis (moderate + severe) (CT alone for breast cancer)
Placebo/no treatment
0.33 - - Not assessed
GRADE Certainty of Evidence:
High Very confident in the effect estimate
Moderate Moderately confident in the effect estimate
Low Limited confidence in the effect estimate
Very Low Very little confidence in the effect estimate

Review Information

Review ID: CD011990
Outcomes: 11 assessed

Related Content

Evidence Quality Distribution:
Not assessed: 11